Position in ANIK
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$14,498
+$9,655 QoQ
Shares Held
991
+196.7% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#96
of 134 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANIK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Allworth Financial LP holds $7,771,550 across 48 Drug Manufacturers - Specialty & Generic names. ANIK ranks #24 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
14,853 | $2,503,324 | |
| 2 | SUPN |
Supernus Pharmaceuticals, Inc.
|
50,669 | $2,356,615 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,167 | $632,315 | |
| 4 | ZTS |
Zoetis Inc.
|
6,658 | $478,443 | |
| 5 | VTRS |
Viatris Inc
|
18,367 | $291,667 | |
| 6 | TAK |
Takeda Pharmaceutical Co Ltd
|
13,516 | $216,661 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
8,616 | $212,039 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
4,826 | $174,701 |
All Filings in ANIK
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,498 | 991 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $4,843 | 334 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $96 | 10 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $103 | 11 | Shares | Sole | 2025-12-02 | |
| 2025-06-30 | $126 | 12 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||